|
1
|
Moskowitz C: Diffuse large B cell
lymphoma: How can we cure more patients in 2012? Best Pract Res
Clin Haematol. 25:41–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pileri SA, Agostinelli C, Sabattini E,
Bacci F, Sagramoso C, Pileri A Jr, Falini B and Piccaluga PP:
Lymphoma classification: The quiet after the storm. Semin Diagn
Pathol. 28:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abid MB, Nasim F, Anwar K and Pervez S:
Diffuse large B cell lymphoma (DLBCL) in Pakistan: An emerging
epidemic? Asian Pac J Cancer Prev. 6:531–534. 2005.PubMed/NCBI
|
|
4
|
Song CG, Huang JJ, Li YJ, Xia Y, Wang Y,
Bi XW, Jiang WQ, Huang HQ, Lin TY and Li ZM: Epstein-barr
virus-positive diffuse large B-cell lymphoma in the elderly: A
matched case-control analysis. PLoS One. 10:e01339732015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harris NL, Jaffe ES, Diebold J, Flandrin
G, Muller-Hermelink HK and Vardiman J: Lymphoma classification-from
controversy to consensus: The R.E.A.L. and WHO Classification of
lymphoid neoplasms. Ann Oncol. 11:(Suppl 1). S3–S10. 2000.
View Article : Google Scholar
|
|
6
|
Coiffier B: Rituximab therapy in malignant
lymphoma. Oncogene. 26:3603–3613. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised International Prognostic Index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He X, Chen Z, Fu T, Jin X, Yu T, Liang Y,
Zhao X and Huang L: Ki-67 is a valuable prognostic predictor of
lymphoma but its utility varies in lymphoma subtypes: Evidence from
a systematic meta-analysis. BMC Cancer. 14:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song MK, Chung JS, Lee JJ, Yang DH, Kim
IS, Shin DH and Shin HJ: High Ki-67 expression in involved bone
marrow predicts worse clinical outcome in diffuse large B cell
lymphoma patients treated with R-CHOP therapy. Int J Hematol.
101:140–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W,
Wei WX, Jiang WQ, Lin TY, Huang HQ and Guan ZZ: High Ki-67
expression in diffuse large B-cell lymphoma patients with
non-germinal center subtype indicates limited survival benefit from
R-CHOP therapy. Eur J Haematol. 88:510–517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hasselblom S, Ridell B, Sigurdardottir M,
Hansson U, Nilsson-Ehle H and Andersson PO: Low rather than high
Ki-67 protein expression is an adverse prognostic factor in diffuse
large B-cell lymphoma. Leuk Lymphoma. 49:1501–1509. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jerkeman M, Anderson H, Dictor M, Kvaløy
S, Akerman M and Cavallin-Ståhl E: Nordic Lymphoma Group study:
Assessment of biological prognostic factors provides clinically
relevant information in patients with diffuse large B-cell
lymphoma-a Nordic Lymphoma Group study. Ann Hematol. 83:414–419.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ali HR, Dawson SJ, Blows FM, Provenzano E,
Leung S, Nielsen T, Pharoah PD and Caldas C: A Ki67/BCL2 index
based on immunohistochemistry is highly prognostic in ER-positive
breast cancer. J Pathol. 226:97–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iqbal J, Meyer PN, Smith LM, Johnson NA,
Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, et
al: BCL2 predicts survival in germinal center B-cell-like diffuse
large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Clin Cancer Res. 17:7785–7795. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iqbal J, Neppalli VT, Wright G, Dave BJ,
Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner
TC, et al: BCL2 expression is a prognostic marker for the activated
B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol.
24:961–968. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pfreundschuh M, Ho AD, Cavallin-Stahl E,
Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL,
Mingrone W, et al: Prognostic significance of maximum tumour (bulk)
diameter in young patients with good-prognosis diffuse large-B-cell
lymphoma treated with CHOP-like chemotherapy with or without
rituximab: An exploratory analysis of the MabThera International
Trial Group (MInT) study. Lancet Oncol. 9:435–444. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu S, Xu-Monette ZY, Tzankov A, Green T,
Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, et al:
MYC/BCL2 protein coexpression contributes to the inferior survival
of activated B-cell subtype of diffuse large B-cell lymphoma and
demonstrates high-risk gene expression signatures: A report from
The International DLBCL Rituximab-CHOP Consortium Program. Blood.
121:4021–4031. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson NA, Slack GW, Savage KJ, Connors
JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et
al: Concurrent expression of MYC and BCL2 in diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol. 30:3452–3459. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Green TM, Young KH, Visco C, Xu-Monette
ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T,
Frederiksen M, et al: Immunohistochemical double-hit score is a
strong predictor of outcome in patients with diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol. 30:3460–3467. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mationg-Kalaw E, Tan LH, Tay K, Lim ST,
Tang T, Lee YY and Tan SY: Does the proliferation fraction help
identify mature B cell lymphomas with double- and triple-hit
translocations? Histopathology. 61:1214–1218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akyurek N, Uner A, Benekli M and Barista
I: Prognostic significance of MYC, BCL2, and BCL6 rearrangements in
patients with diffuse large B-cell lymphoma treated with
cyclophosphamide, doxorubicin, vincristine, and prednisone plus
rituximab. Cancer. 118:4173–4183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilson KS, Sehn LH, Berry B, Chhanabhai M,
Fitzgerald CA, Gill KK, Klasa R, Skinnider B, Sutherland J, Connors
JM and Gascoyne RD: CHOP-R therapy overcomes the adverse prognostic
influence of BCL-2 expression in diffuse large B-cell lymphoma.
Leuk Lymphoma. 48:1102–1109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mounier N, Briere J, Gisselbrecht C, Emile
JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, et
al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated
resistance to chemotherapy in elderly patients with diffuse large
B-cell lymphoma (DLBCL). Blood. 101:4279–4284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Montraveta A, Xargay-Torrent S, Rosich L,
López-Guerra M, Roldán J, Rodríguez V, Lee-Vergés E, de Frías M,
Campàs C, Campo E, et al: Bcl-2high mantle cell lymphoma cells are
sensitized to acadesine with ABT-199. Oncotarget. 6:21159–21172.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cervantes-Gomez F, Lamothe B, Woyach JA,
Wierda WG, Keating MJ, Balakrishnan K and Gandhi V: Pharmacological
and protein profiling suggests venetoclax (ABT-199) as optimal
partner with ibrutinib in chronic lymphocytic Leukemia. Clin Cancer
Res. 21:3705–3715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Klanova M, Andera L, Brazina J, Svadlenka
J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman
K, et al: Targeting of BCL2 family proteins with ABT-199 and
homoharringtonine reveals BCL2- and MCL1-Dependent subgroups of
diffuse large B-cell lymphoma. Clin Cancer Res. 22:1138–1149. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shao Q, Kannan A, Lin Z, Stack BC Jr, Suen
JY and Gao L: BET protein inhibitor JQ1 attenuates Myc-amplified
MCC tumor growth in vivo. Cancer Res. 74:7090–7102. 2014.
View Article : Google Scholar : PubMed/NCBI
|
